Skip to content
A7928Assembly2021-2022 Session

Establishes the psychedelic research institute and the psychedelic substances therapeutic research program

Sponsor Linda RosenthalAD-67Affects Health
Status
In Assembly Committee
Health
Impact
Pending
Passage
Pending

Bill progress

Step 2 of 7

In committee · Health

What's happening

Summary being written. Track this bill to get it by email.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Sponsors

Primary sponsor
Linda Rosenthal

Assembly Member · Assembly District 67

No co-sponsors yet.

History

  1. Referred to health
  2. Referred to health

Full text

6 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

7928

2021-2022 Regular Sessions

IN ASSEMBLY

June 1, 2021

Introduced by M. of A. L. ROSENTHAL -- read once and referred to the Committee on Health

AN ACT to amend the public health law, in relation to establishing the psychedelic research institute and the psychedelic substances therapeutic research program

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. The public health law is amended by adding a new article 27-G to read as follows:

ARTICLE 27-G

PSYCHEDELIC RESEARCH INSTITUTE Section 2788. Legislative findings.

2789. Definitions.

2790. The institute for therapeutic psychedelics research.

2791. Powers and duties.

2792. Research council.

2793. Advisory council.

2794. Reports by the commissioner.

§ 2788. Legislative findings. The legislature finds that recent research provides a growing body of evidence that 1. the use of psychedelics such as ibogaine, LSD, psilocybin and certain other psychedelic drugs in certain settings may provide a treatment for people struggling with a substance use disorder, including methamphetamine, opioids, and other addictive substances; 2. 3, 4-methylenedioxymethamphetamine (MDMA) may be efficacious in treatment of post-traumatic stress disorder (PTSD) and alcoholism; 3. psilocybin is a breakthrough therapy for severe depression and nicotine addiction; and 4. other psychedelic substances also may be efficacious in treatment of other illnesses and maladies. It is for the purpose of facilitating clinical programs for such research and investigation into the safety and efficacy of psychedelic substances

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD11370-02-1

A. 7928 2

for treatment of human illnesses and maladies that the psychedelic substances therapeutic research act is hereby enacted.

§ 2789. Definitions. For purposes of this article, the following terms shall have the following meanings:

1. "Psychedelic substance" means any substance listed in paragraph (d) of schedule I of section thirty-three hundred six of this chapter.

2. "Principal investigator" means an individual who actually conducts a clinical investigation, i.e., under whose immediate direction the test article is administered or dispensed to, or used involving, a subject, or, in the event of an investigation conducted by a team of individuals, is the responsible leader of that team.

3. "Hospital" shall have the same meaning as defined pursuant to section twenty-eight hundred one of this chapter.

4. "Clinic" shall mean a site where a licensed or otherwise recognized practitioner or group provides care to patients and/or individuals seeking therapeutic interventions using psychedelic substances as listed herein.

5. "Internal review board" or "IRB" means an appropriately constituted group that has been formally designated to review and monitor biomedical research involving human subjects. In accordance with food and drug administration regulations, an IRB shall have the authority to approve, require modifications in (to secure approval), or disapprove research. IRB group review shall serve an important role in the protection of the rights, safety and welfare of human research subjects.

§ 2790. The institute for therapeutic psychedelics research. 1. There is hereby established within the department the public institute for therapeutic psychedelics research (ITPR). The institute shall have the central responsibility for administering the provisions of this article and otherwise coordinating the state's policies with respect to the use of psychedelic substances in treatment of substance use disorders, depression, post-traumatic stress disorder, end-of-life anxiety and other conditions.

2. The commissioner shall appoint a director of the institute and may assign such personnel within the amounts appropriated as is necessary to carry out the provisions of this article.

3. The state of New York shall designate such spaces within existing state-owned or operated facilities or buildings, or in conjunction with local departments of health, to establish a headquarters and, as appropriate clinics to conduct clinical trials of psychedelic substances for appropriate clinical outcomes, including, but not limited to, substance use disorders, depression, end-of-life anxiety and post-traumatic stress disorder.

§ 2791. Powers and duties. 1. The institute shall have the following powers and duties:

(a) to coordinate, develop and promote clinical programs and trials with appropriate methodologies to study and investigate the safety and efficacy of psychedelics for various outcomes, and assist in the coordination of extramural clinical studies, including as needed, access to psychedelic agents and other programmatic needs;

(b) to develop and promote programs of professional education and training and improvements in instrumentation as necessary adjuncts to such scientific investigations;

(c) to form an institutional review board to provide oversight in proposed clinical trials of psychedelic compounds, particularly to assist principal investigators at sites lacking formal institutional review board oversight;

A. 7928 3

(d) to develop and maintain a clearinghouse within the department for information collected on the safety and efficacy of psychedelic substances as well as to provide a registry for all outcomes of clinical trials and studies, including a catalog of the existing medical literature and the results of existing epidemiological studies;

(e) to develop and promote an outreach campaign directed toward people struggling with substance use disorder, depression, post-traumatic stress disorder, anxiety, alcoholism and nicotine addiction to promote the availability of psychedelic compounds as a treatment through clinical programs established hereunder as well as any clinical research and investigative programs that studies and investigates the safety and efficacy of psychedelic substances; and

(f) to promote the availability of any other supportive services for people struggling with substance use disorder, depression, post-traumatic stress disorder, anxiety, alcoholism and nicotine addiction as well as long term outcomes after treatment for such conditions or other aforementioned indications.

2. Personal data in any investigations, reports and information relating to the provisions of this article shall be kept confidential and anonymous, shall be afforded all of the protections provided by the provisions of paragraph (j) of subdivision one of section two hundred six of this chapter, and are hereby made subject to part two of title forty-two of the Code of Federal Regulations. The institute may however, from time to time, publish reports of such scientific investigations in such a manner as to assure that the identities of the individuals concerned cannot be ascertained.

§ 2792. Research council. 1. There shall be established within IPTR a research council composed of fifteen members; four members to be appointed by the temporary president of the senate, one member to be appointed by the minority leader of the senate, four members to be appointed by the speaker of the assembly, one member to be appointed by the minority leader of the assembly and five members to be appointed by the commissioner. The members shall be representative of recognized centers engaged in the scientific investigation of substance abuse disorders and/or the use of psychedelics in treatment of pertinent outcomes.

2. The research council shall be responsible for making recommendations to the institute for the purpose of carrying out the provisions of paragraphs (a) and (b) of subdivision one of section twenty-seven hundred ninety-one of this article, as well as appointing members of the internal review board as provided for in paragraph (c) of subdivision one of section twenty-seven hundred ninety-one of this article.

3. The council shall meet at least six times a year. Special meetings may be called by the chairperson and shall be called by him or her at the request of the commissioner.

4. The members of the council shall receive no compensation for their services, but shall be allowed their actual and necessary expenses incurred in the performance of their duties hereunder.

§ 2793. Advisory council. 1. There shall be established within IPTR an advisory council composed of thirteen members who shall be appointed in the following manner: three shall be appointed by the temporary president of the senate and one by the minority leader of the senate; three shall be appointed by the speaker of the assembly and one by the minority leader of the assembly; and five shall be appointed by the governor. The governor shall designate the chairperson of the advisory council. The members of the council shall be representative of the public, educa-

A. 7928 4

tional and medical institutions, local health departments, and nonprofit organizations, including organizations and individuals qualified through degree and/or experience presently providing psychedelic substances as a treatment modality for people struggling with a substance use disorder, depression, post-traumatic stress disorder, anxiety, alcoholism and nicotine addiction.

2. The advisory council shall be responsible for advising the commissioner with respect to the implementation of this article and shall make recommendations to the institute for the purpose of carrying out the provisions of paragraphs (d), (e), and (f) of subdivision one of section twenty-seven hundred ninety-one of this article.

3. The advisory council shall include at least four members of affected communities, provisions for a stipend, travel or other expenses to be established to provide insight and support from the community perspective in the development of clinical trial protocols.

4. The council shall meet at least four times a year. Special meetings may be called by the chairperson and shall be called by him or her at the request of the commissioner.

§ 2794. Reports by the commissioner. The institute shall make an initial preliminary report to the governor and the legislature of its findings, conclusions, and recommendations not later than December first, two thousand twenty-one, a second preliminary report of its findings, conclusions, and recommendations not later than December first, two thousand twenty-two, and a report of its findings, conclusions, and recommendations with regard to the progress made in developing, promoting and completing clinical evaluations not later than December first, two thousand twenty-three, and shall submit with its reports such legislative proposals as it deems necessary to implement its recommendations.

§ 2. The public health law is amended by adding a new article 33-AA to read as follows:

ARTICLE 33-AA

PSYCHEDELIC SUBSTANCES THERAPEUTIC RESEARCH ACT Section 3397-j. Psychedelic substances therapeutic research program

established; participation.

3397-k. State patient qualification board; composition; powers

and duties.

3397-l. Psychedelic substances research program; cultivation and

distribution.

§ 3397-j. Psychedelic substances therapeutic research program established; participation. 1. The psychedelic substances therapeutic research program is hereby established in the department. The commissioner shall promulgate rules and regulations necessary for the proper administration of the psychedelic substances therapeutic research program. In such promulgation, the commissioner shall take into consideration the reports of the psychedelics research institute and pertinent rules and regulations of the food and drug administration.

2. Participation in the psychedelics substances therapeutic research program shall be limited to persons eligible for participation by the internal review board (IRB)-approved inclusion and exclusion criteria of proposed clinical study. Outcome-directed clinical trials and evaluations may include persons addicted to opiates or methamphetamine, persons suffering from post-traumatic stress disorder (PTSD), or persons suffering from severe depression, as appropriate to the trial design registered with the public institute for therapeutic psychedelics research (ITPR) and the protocols specified in 42 CFR 11.

A. 7928 5

3. Where pertinent, participants in ITPR studies or evaluations should receive the current standard of care. Stakeholder community members will be consulted regarding proposed clinical trials for their or other studies, case series or other appropriate methodologies for evaluating the efficacy of psychedelic substances.

4. The commissioner, on behalf of the department, shall apply to the food and drug administration (FDA) for an investigational new drug permit for any of the psychedelic agents listed in section twenty-seven hundred eighty-eight of this chapter, including but not limited to ibogaine, psilocybin, LSD, cannabis, MDMA, DMT and other such agents within ninety days after the effective date of this section. The commissioner, on behalf of the department, may apply to the FDA for an investigational new drug (IND) permit for any other psychedelic substance as the commissioner deems appropriate. The commissioner shall continue to fulfill all of his or her duties hereunder unless and until this article is repealed.

§ 3397-k. State patient qualification board; composition; powers and duties. 1. The commissioner shall appoint a state patient qualification review board of no less than three nor more than five members. The state patient qualification review board shall be comprised of:

(a) a physician licensed to practice medicine in New York state and certified by the American board of internal medicine;

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.